Wilsons Sticks to Its Buy Rating for SmartPay Holdings Limited (KX2)
Wilsons analyst Cameron Halkett maintained a Buy rating on SmartPay Holdings Limited (KX2 – Research Report) on June 23 and set a price target of A$1.20. The company's shares closed last Monday at €0.52.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Halkett is a 3-star analyst with an average return of 3.0% and a 52.08% success rate. Halkett covers the Financial sector, focusing on stocks such as OFX Group Ltd., HUB24 Limited, and Pinnacle Investment Management Group Limited.
Currently, the analyst consensus on SmartPay Holdings Limited is a Moderate Buy with an average price target of €0.61.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nuvalent price target raised to $140 from $125 at Leerink
Leerink raised the firm's price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent's zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by 'unprecedented' durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of therapy. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NUVL: Disclaimer & DisclosureReport an Issue Nuvalent price target raised to $130 from $110 at H.C. Wainwright Nuvalent's Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile Nuvalent Announces Positive Data for Zidesamtinib Trial Nuvalent Announces New Director and Annual Meeting Results Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nuvalent price target raised to $130 from $110 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluating zidesamtinib to treat ROS1-positive non-small cell lung cancer patients that have received prior (tyrosine kinase inhibitor therapy, the analyst tells investors in a research note. The firm says the overall response rate among all patients is 44%, and the patients showed good durability with duration of responses of 78% at 12 months and 62% at 18 months. H.C. Wainwright believes the data was 'particularly encouraging' in the 55 patients who received only one prior line of TKI therapy, who achieved overall response rate of 51% and an 18- month duration of response of 93%. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NUVL: Disclaimer & DisclosureReport an Issue Nuvalent's Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile Nuvalent Announces Positive Data for Zidesamtinib Trial Nuvalent Announces New Director and Annual Meeting Results Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating Nuvalent Board Member Emily Conley Resigns Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Microsoft to conduct another round of layoffs at Xbox division, Bloomberg says
Microsoft (MSFT) will conduct another round of major layoffs in its Xbox division this week, with managers expecting substantial cuts across the entire group, Jason Schreier of Bloomberg reports, citing people familiar with the plans. This will be the fourth big layoff at Xbox within the last 18 months. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on MSFT: Disclaimer & DisclosureReport an Issue Trump Trade: Trump slams Powell while Fed chair appears before Congress Quantum Computing News: New Roadmaps, Real Timelines, and Rising Stocks Top Analyst Views Microsoft Stock (MSFT) as a 'Key Beneficiary of AI Adoption' Video Game Layoffs Continue with Cuts at MindsEye and Splitgate 2 Studios Is ChatGPT Dumbing Us Down? MIT Study Says Yes Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
